ArriVent BioPharma, Inc. (AVBP) News
Follow ArriVent BioPharma, Inc. (AVBP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:12 PM UTC
M
ArriVent BioPharma Shares Rise 9.3% on Initial Cancer Trial Data
Shares gained 9.3% to $22.95 in premarket trading after ArriVent announced positive initial Phase 1 data for a gastrointestinal cancer treatment. The body is truncated after “The drug con”.
EQUITY | Oct 26, 2026, 11:21 AM UTC
M
ArriVent Reports 44.8% Response Rate for ARR-217 in Phase 1 CRC Data
ArriVent BioPharma reported initial Phase 1 data showing a 44.8% objective response rate among pretreated colorectal cancer patients at the 6 mg/kg dose.
EQUITY | Oct 26, 2026, 10:03 AM UTC
H
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling around 1% on Wednesday. Shares of BKV Corp (NYSE: BKV ) rose sharply after the company announced that a subsidiary executed into a n equipment supply contract. BKV
LIVE | Oct 07, 2026, 02:08 PM UTC
H
ArriVent BioPharma Shares Plunge Over 48% After Lung Cancer Trial Fails
ArriVent BioPharma (AVBP) shares plummeted over 48% to an all-time low on Tuesday after the company announced its experimental lung-cancer treatment failed to meet the primary endpoint of a Phase 3 trial. This marks the
EQUITY | Oct 06, 2026, 05:51 PM UTC
H
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones index surging around 350 points on Tuesday. The Dow traded up 0.69% to 51,622.17 while the NASDAQ jumped 0.79% to 27,694.08. The S&P 500 also rose, gai
LIVE | Oct 06, 2026, 04:04 PM UTC
H
ArriVent BioPharma Stock Plunges 54% on Disappointing Drug Trial Results
ArriVent BioPharma shares fell 54% to $13 on Tuesday, marking its largest single-day decline, following the release of disappointing results for its lung-cancer drug.
EQUITY | Oct 06, 2026, 03:54 PM UTC
H
ArriVent BioPharma Lung Cancer Drug Fails Phase 3 Trial
ArriVent BioPharma announced that its experimental treatment for a type of lung cancer did not meet the primary endpoint in a Phase 3 clinical trial. The company's stock fell 59% in premarket trading following the news.
EQUITY | Oct 06, 2026, 12:52 PM UTC
M
ArriVent Lung Cancer Treatment Fails Late-Stage Trial
ArriVent BioPharma announced that its therapy for a specific type of lung cancer did not achieve its primary objective in a late-stage clinical trial.
EQUITY | Oct 06, 2026, 12:13 PM UTC
L
ArriVent BioPharma Reports Q2 2026 Results
ArriVent BioPharma reports second quarter 2026 financial results
EARNINGS | Aug 12, 2026, 08:01 PM UTC